Immunovant, Inc. (IMVT) Tops Q3 EPS by 7c

Immunovant, Inc. (NASDAQ: IMVT) reported Q3 EPS of ($0.36), $0.07 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Immunovant, Inc. (IMVT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M